Regulation of viability, differentiation and death of human melanoma cells carrying neural stem cell biomarkers: a possibility for neural trans-differentiation by Ivanov, Vladimir N. & Hei, Tom K.
ORIGINAL PAPER
Regulation of viability, differentiation and death of human
melanoma cells carrying neural stem cell biomarkers: a possibility
for neural trans-differentiation
Vladimir N. Ivanov1 • Tom K. Hei1
Published online: 8 May 2015
 Springer Science+Business Media New York 2015
Abstract During embryonic development, melanoblasts,
the precursors of melanocytes, emerge from a subpopulation
of the neural crest stem cells and migrate to colonize skin.
Melanomas arise during melanoblast differentiation into
melanocytes and from young proliferating melanocytes
through somatic mutagenesis and epigenetic regulations. In
the present study, we used several human melanoma cell
lines from the sequential phases of melanoma development
(radial growth phase, vertical growth phase and metastatic
phase) to compare: (i) the frequency and efficiency of the
induction of cell death via apoptosis and necroptosis; (ii) the
presence of neural and cancer stem cell biomarkers as well as
death receptors, DR5 and FAS, in both adherent and spheroid
cultures of melanoma cells; (iii) anti-apoptotic effects of the
endogenous production of cytokines and (iv) the ability of
melanoma cells to perform neural trans-differentiation. We
demonstrated that programed necrosis or necroptosis, could
be induced in two metastatic melanoma lines, FEMX and
OM431, while the mitochondrial pathway of apoptosis was
prevalent in a vast majority of melanoma lines. All me-
lanoma lines used in the current study expressed substantial
levels of pluripotency markers, SOX2 and NANOG. There
was a trend for increasing expression of Nestin, an early
neuroprogenitor marker, during melanoma progression.
Most of the melanoma lines, including WM35, FEMX and
A375, can grow as a spheroid culture in serum-free media
with supplements. It was possible to induce neural trans-
differentiation of 1205Lu and OM431 melanoma cells in
serum-free media supplemented with insulin. This was
confirmed by the expression of neuronal markers, dou-
blecortin and b3-Tubulin, by significant growth of neurites
and by the negative regulation of this process by a dominant-
negative Rac1N17. These results suggest a relative plasticity
of differentiated melanoma cells and a possibility for their
neural trans-differentiation without the necessity for pre-
liminary dedifferentiation.
Keywords Melanoma  Apoptosis  Necroptosis  Neural
stem cells  Transdifferentiation
Abbreviations
EGF Epidermal growth factor
ERK1/2 Extracellular-signal-regulated kinases
FACS Fluorescence-activated cell sorter
FGF2 Fibroblast growth factor-2 (basic)
IjB Inhibitor of NF-jB
IKK Inhibitor nuclear factor kappa B kinase
JNK C-Jun N-terminal kinase
MAPK Mitogen-activated protein kinase
MEK MAPK/ERK kinase
NF-jB Nuclear factor kappa B
NSC Neural stem cells
PARP-1 Poly (ADP-ribose) polymerase-1
PI Propidium iodide
PI3K Phosphoinositide 3-kinase
STAT Signal transducers and activators of
transcription
TNFa Tumor necrosis factor
Electronic supplementary material The online version of this
article (doi:10.1007/s10495-015-1131-3) contains supplementary
material, which is available to authorized users.
& Vladimir N. Ivanov
vni3@cumc.columbia.edu
1 Center for Radiological Research, Department of Radiation
Oncology, College of Physicians and Surgeons, Columbia








Significant progress has been made during the last 15 years
in new molecule targeted therapies for treatment of ad-
vanced cancers, including melanomas. There are several
dominant genetic alterations during melanoma carcino-
genesis: (i) BRAF and NRAS gene mutations [1–3], which
were found in nearly 50–60 and 20 % of melanomas, re-
spectively; (ii) deletion of the CDKN2A locus, which en-
coded two tumor suppressor proteins, p16INK4a and
p14ARF, was found in up to 50 % of melanomas [4]; (iii)
deletion or mutation of PTEN, an endogenous inhibitor of
PI3K-AKT, was found in 20 % of melanomas [5]; (iv)
finally, mutations of TP53 were found in 19 % of me-
lanomas [6]. Small molecule inhibitors, such as vemu-
rafenib, suppress permanently active mutated BRAF that
results in the arrest of proliferation and the subsequent
death of melanoma cells in vitro and in vivo during patient
treatment [1, 7]. A complementary approach to improve the
survival of patients with metastatic melanoma is based on
the usage of immune-stimulating monoclonal antibodies,
which suppress endogenous inhibitors of the immune re-
sponse: ipilimumab that blocks CTLA-4 [8] and nivolumab
that blocks PD-1 receptor [9]. Unfortunately, tumor relapse
frequently follows within several months in patients treated
with specific molecule inhibitors or after immunostimula-
tion [10, 11].
Resistance of melanoma to therapy is, in general, a re-
sult of Darwinian selection among the strongly heteroge-
neous population of cancer clones with dramatic genomic
instability [12], which is accompanied by genetic, epige-
netic or microenvironmentally regulated suppression of
proapoptotic signaling pathways in these clones in concert
with overactivation of the prosurvival and proliferative
pathways [13]. Typical examples of the selective pressure
for cancer cell survival are overactivation of CRAF after
stable inhibition of BRAF [14] and overactivation of
STAT3 in the case of use of MEK-ERK inhibitors in me-
lanoma cells [15, 16]. Such compensatory mechanisms for
reestablishing activity of critical signaling proteins and
enzymes in cancer cells after treatment could be based on
metabolic regulation, crosstalk in the cell signaling net-
works or, finally, on gene mutations. Comprehensive ana-
lysis of a landscape of driver mutations in melanoma
indeed revealed several novel mutations, including RAC1
P29S (4–9 % of patient’s melanomas) that confers resis-
tance to pharmacological inhibition of BRAF [6, 17].
Additionally, a role for activation of Notch1 signaling in
promoting resistance to MAPK inhibitors in BRAF V600K
mutated cells was highlighted [18]. Hence, a suppression of
tumor cell proliferation/survival through combined inhibi-
tion of distinctive signaling pathways [19], as well as
reestablishing of effective induction of cell death in resis-
tant metastatic melanoma cells appear to be a predominant
therapeutic goal. Selection pressure for cancer cell survival
may target signal-dependent regulation of gene expression
and epigenetic control mechanisms that often precede so-
matic mutations, which could in turn affect the similar
downstream functions. On the other hand, stochastic mu-
tagenesis in dividing cells, especially in conditions favor-
able to genomic instability, might be the main factor of the
creation of somatic clones with numerous mutations, in-
cluding driver mutations, which predetermine the cell
malignancy [20].
However, the original stochastic model of somatic mu-
tagenesis and selection of cancerous clones [12] was
challenged by elucidation of cancer initiating cells, which
in many cases are close relatives to normal stem cells. The
alternative ‘‘hierarchical’’ model suggests that genomic
instability at the levels of the self-renewal and differen-
tiation of stem or precursor cells may result in their neo-
plastic conversion into cancer initiating cells or ‘‘cancer
stem cells’’ [21, 22]. According to this model, a tumor at
the state of progression is composed of cell subpopulations
in different phases of differentiation as a large group of
rapidly dividing differentiated cells and a relatively small
group of slowly dividing cells with a stem cell-like phe-
notype. Extensive investigation of cancer initiating cell
subpopulations in different types of tumors revealed,
however, that the percentage of cancer initiating cells
among the total number of cancer cells exhibit a dramatic
variation from 0.1 % to almost 100 % [22, 23].
The existence of melanoma initiating cells or ‘‘me-
lanoma stem cells’’ has also been suggested for this type of
cancer [24, 25]. However, it still remains a controversial
problem [26, 27] due to a strong variation in the percentage
of cancer initiating cells in different melanoma lines and
patient’s samples, in addition to uncertainty in the speci-
ficity of biomarkers. Melanoma initiating cells could be
identified via expression of different biomarkers such as
CD133, ABCB5, NGFR, SOX10, CD20, CD166, and some
others [28–32]. However, there is no final consensus on this
subject. Therefore, further elucidation of molecular
mechanisms underlying the regulation of melanocyte stem
cells (melanoblasts) and their possible linkage with the
melanoma initiating cells are especially important for the
development of novel therapeutic strategies for melanocyte
malignancy.
Cancer progression and development, including me-
lanoma, are tightly linked with the regulation of cell death.
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Programmed death of normal and cancer cells is executed
via two main mechanisms, apoptosis and programmed
necrosis (or necroptosis), which are modulated by numer-
ous genetic, epigenetic and metabolic regulators (including
misfolded protein stress, macroautophagy and mitophagy)
that finally result in positive or negative effects on survival
of normal and cancer cells. The significance of the induc-
tion of apoptosis (in its two forms, the exogenous death
ligand/death receptor-dependent and the endogenous mi-
tochondria-dependent death signaling pathways) to cure
cancer is well established [6, 13, 33, 34], while a role for
regulated necrosis [35, 36] in cancer cells is still unknown
since it is not completely investigated. In the present study,
we used several human melanoma cell lines from the
subsequent phases of melanoma development (radial
growth phase, vertical growth phase and metastatic phase)
[37], to compare: (i) frequency and efficiency of the in-
duction of cell death via apoptosis and necroptosis; (ii) the
presence of neural and cancer stem cell biomarkers as well
as death receptors, DR5 FAS and TNFR1, in adherent and
spheroid cultures of melanoma cells; and iii) the ability of
melanoma cells to perform neural trans-differentiation.
Results
Expression of regulators of pluripotency and neural
stem cell biomarkers in human melanoma lines
from the subsequent phases of cancer development
In the present study, we used eight well-characterized
melanoma cell lines (Fig. 1a) that were isolated from dif-
ferent phases of melanoma progression [38, 39] with
established BRAF and PTEN status [16, 40]; see also a
table of melanoma lines with BRAF and PTEN status by
M. Herlyn (http://www.wistar.org/lab/meenhard-herlyn-
dvm-dsc/page/melanoma-cell-lines-0). Embryonic neural
stem cells (NSC), which are in close relation to neural crest
stem cells (NCSC), the ancestors of melanoblasts, have
been used as reference cells with high levels of expression
of master regulators of pluripotency, such as SOX2 and
NANOG, and stem cell biomarkers, CD133 and NGFR
(Fig. 1b, c). Most of NSC are positive for FAS and TRAIL-
R2/DR5 (Fig. 1b) that could be involved in the initiation of
death signaling cascades and, alternatively, under specific
circumstances in protective signaling in cancer stem cells
[41]. NSC are commercially available and could be easily
cultured in serum-free media supplemented with EGF
(20 ng/ml), FGF2 (20 ng/ml) and insulin (5 lg/ml). Me-
lanoblasts are known as potentially multipotent cells that
could differentiate not only into melanocytes but occa-
sionally into neurons and glial cells [42]. U87MG
glioblastoma was used as an additional reference cancer
cell line with well-established characteristics of gene ex-
pression and malignancy. All eight melanoma lines ex-
hibited high protein expression levels of SOX2, with
preferential nuclear and perinuclear localization (Fig. 1c).
However, Nestin, an early neuroprogenitor marker, was
almost completely absent in WM35 radial growth phase
(RGP) melanoma cells and was present approximately in
40 % of WM793 vertical growth phase (VGP) melanoma
cells (Fig. 1c, d). 1205Lu cells, which were established
using a lung metastasis developed in nude mice with hu-
man WM793 xenotransplant [43], demonstrated 100 %
presence of Nestin. Furthermore, all metastatic melanoma
lines used in the current study exhibited high Nestin ex-
pression. However, Nestin was not detected in U87MG
glioblastoma cells that were positive for SOX2 protein
expression (Fig. 1c).
Next we performed a broader comparison of WM35,
WM793 and WM9 human melanoma cells, which repre-
sented RGP, VGP and metastatic phases, respectively, for
the presence of pluripotency markers and critical signaling
proteins (Figs. 1 and 2). NSC was again used as reference
line. High levels of SOX2 and pronounced levels ofNANOG
protein expression were detected in these cell lines (Fig. 2a,
d). Variable levels of other important transcription factors,
such as NF-jB (total and active phosphorylated forms) and
STAT3, as well of signaling kinases MAPK p38, ERK1/2
and AKT (total and active forms) were revealed by Western
blot assay (Fig. 2d). High levels of phospho-ERK were de-
tected in confocal images of WM9 cells, while the hetero-
geneous distribution of phospho-ERK among WM793 cells
with low, intermediate and high kinase levels was observed.
WM35 cells demonstrated low to average levels of basal
phospho-ERK and very low, almost undetectable levels of
Nestin (Fig. 2a, b). After total protein isolation, decreased
basal levels of phospho-ERK (normalized to total ERK and
total protein level) were observed in WM35 cells lines using
Western blot assay (Fig. 2d). Constitutive activity of ERK in
melanoma cells is regulated at two levels (i) via permanently
active mutated BRAF and (ii) via inducible activation of
growth receptor tyrosine kinases resulting in high levels of
CRAF and ERK activity in metastatic melanoma cells [44].
This results in different levels of ERK activity in three me-
lanoma lines,WM35,WM793 andWM9, which have BRAF
V600E.
NGFR, a lineage marker of neural crest stem/progenitor
cells and melanoma initiated cells [28], was expressed on
the surface of a vast majority of WM793 (VGP) and
metastatic WM9 cells, but was revealed only at low levels
in WM35 (RGF) cells and NSC (Fig. 2c). In contrast,
CD133, a potential marker for several types of cancer stem
cells, was present at high surface levels in a majority of
NSC, modestly on the WM35 surface and as a minor
subpopulation (only 1 %) with low surface levels in
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WM793 and WM9 cells (Fig. 2c). Similarly, TNFR1 and
TNFR2 demonstrated intermediate levels of surface ex-
pression in NSC, while these receptors were poorly de-
tectable on the surface of melanoma lines (Fig. 2c). After
cell permeabilization with 0.5 % NP40, however, high
intracellular levels of TNFR1 and other receptors, includ-
ing CD133 and NGFR, were revealed in WM35 and WM9
cells (see Fig. 3a, b). Both TNFR1 (TNFRS1A) and NGFR
(TNFRSF16), members of the Tumor necrosis factor re-
ceptor superfamily, possess a similar (initiation of cell
death signaling) and numerous specific features linked to
signal-dependent regulation of gene expression [45].
We used the exogenous recombinant TNFa (20 ng/ml)
alone or in combinationwith cycloheximide (CHX, 1 lg/ml)
for death induction in WM35 and WM9 melanoma cells.
TNF-mediated apoptosis was previously observed at
prominent levels in human NSC [46]. Pronounced levels of
apoptosis in melanoma cells were detected only after com-
bined treatment, suggesting increased availability of TNFR1
for the exogenous TNFa in the presence of CHX. Pan-cas-
pase inhibitor zVAD-fmk (40 lM) partially suppressed TNF
and CHX induced apoptosis and levels of total death
(Fig. 2e, f). In contrast, the presence of Necrostatin-1
(40 lM), which inhibited RIP1 kinase activity and
Fig. 1 Human neural stem cells (NSC) and human melanoma cell
lines used in this study. a NSC, eight human melanoma cell lines and
glioblastoma U87MG were used. BRAF status is indicated: BRAF
wild-type (wt) protein in human NSC, FEMX metastatic (MET)
melanoma and U87MG glioblastoma; BRAF V600E mutated variant
in WM35 radial growth phase (RGP) melanoma cells, WM793
vertical growth phase (VGP), WM9, 1235Lu, HHMSX and A375
metastatic (MET) melanoma cells and OM431 ocular melanomas.
PTEN status: Wild type (wt), Deleted (Del), Hemi-deleted (Hem Del),
Mutated (Mu). b Immunostaining and surface expression of indicated
receptor in NSC that was determined by FACS analysis; percentage
of positive cells is indicated, ns means non-specific staining.
c Confocal analysis of images after immunostaining using rabbit
polyclonal Ab to SOX2, a pluriopotency marker (green) and
monoclonal antibody to Nestin, an early neuroprogenitor marker
(red). Bar = 50 lm. d Percentage of Nestin-positive cells among
melanoma and glioblastoma lines. Error bars represent mean ± SD
(p\ 0.05, Student’s t test). Stars indicate significant difference
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programed necrosis, partially decreased levels of total cell
death inNSC, but not inWM35 andWM9melanoma cells. It
indicated a parallel development of necroptosis and apop-
tosis in NSC and the apparent absence of necroptotic com-
mitment inWM35 andWM9cell after TNF?CHX treatment
(Fig. 2f). Interestingly, a permeabilization of WM35 and
WM9 melanoma cells (which were cultured in complete
media containing 10 % FBS) with 0.5 % NP40 followed by
immunostaining and FACS analysis demonstrated high in-
tracellular pools of NGFR, TNFR1 and CD133 in two me-
lanoma lines, while the vast majority of DR5 (TRAIL-R2)
was already located on the cell surface (Fig. 3a, B and not
shown). This was correlated with high sensitivity of these
melanoma lines to TRAIL-induced apoptosis.
WM35 cells, similar to NSC, formed spheroids in
serum-free media supplemented with FGF2 (20 ng/ml),
EGF (20 ng/ml) and insulin (5 lg/ml) (Fig. 3c, d), and
were able to further grow as a spheroid culture. In contrast,
WM9 metastatic melanoma formed two subpopulations of
floating (live and dead) and adhering (live) cells in serum-
free media, but most of the cells finally died after 8 days in
these conditions (Fig. 3d). Additionally, WM35 spheroids
demonstrated decreased surface expression of DR5 and
acquired resistance to TRAIL-mediated apoptosis,
Fig. 2 TNFa/TNFR-mediated cell death in NSC and in human
melanoma lines WM35, WM793 and WM9 expressing the neural
stem cell markers and TNFR1/2. a and b Confocal analysis of images
after immunostaining using rabbit polyclonal Ab to phospho-ERK
(green) and monoclonal Ab to Nestin (red) or polyclonal Ab to SOX2
(green) and monoclonal Ab to Nestin (red); merged images in yellow/
orange. Bar = 50 lm c Surface expression levels of NGFR, CD133
and TNFR1/2 in NSC and melanoma lines; ns nonstained cells.
Percentage of antigen-positive cells is indicated. d Western blot
analysis of protein expression levels of SOX2 and NANOG,
pluripotency markers, as well as signaling proteins and transcription
factors in NSC (1) and specified melanoma lines (2–4). e Cell cycle-
apoptosis analysis of WM35 and WM9 melanoma cells after
treatment with cycloheximide (CHX) 1 lM, TNFa (20 ng/ml),
zVAD (40 lM) alone or in combination. 48 h after treatment, cells
were stained with PI and analyzed by the flow cytometry. f Total
death levels were determined by Trypan blue exclusion assay. Pooled
results of four independent experiments with indicated treatments are
shown for NSC, WM35 and WM9 cells. zVAD, 40 lM and
Necrostatin (Necro), 40 lM were used. Error bars represent
mean ± SD (p\ 0.05, Student’s t test). Stars and triangulars
indicate significant differences
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compared to cells that were cultured in the complete media
(Fig. 3e, f). In contrast, low surface, but high total ex-
pression of TNFR1 in WM35 spheroids maintained
relatively stable levels of TNF-mediated apoptosis
(Fig. 3f). We hypothesized that the WM35 early melanoma
cell population was enriched by potential cancer initiating
cells, which became more evident in stress conditions, such
as apoptotic commitment or growth as a spheroid culture in
serum-free media. Indeed, previously published data
demonstrated increased tumorigenicity of WM35 cells
from spheroid culture, compared to the WM35 adherent
culture [47].
The integrity of mitochondria in the cell and general cell
survival are strongly dependent from two signaling path-
ways PI3K-AKT and IKK-NF-jB [48, 49]. Furthermore,
IKK-NF-jB pathway controls expression of numerous
genes, including genes encoding proinflammatory cytoki-
nes, TNFSF1A (TNFa), IL6 and IL8, and COX2 [48, 50].
Since PTEN, an endogenous inhibitor of PI3K-AKT
pathway, is frequently mutated/deleted in melanomas [3],
the basal AKT activity could be well pronounced in me-
lanoma lines. To elucidate the possibility of the induction
of mitochondrial death pathways in NSC and WM35 or
WM9 melanoma cells, we used a strong proapoptotic po-
tential of combined inhibition of these main survival
pathways by small molecule inhibitors of IKKb-NF-jB
(BMS345541) and PI3K-AKT (LY294002) (Suppl. Fig-
ure 1). We recently observed high levels of apoptosis in-
duced by such treatment in glioblastoma cells [51]. A
combination of BMS345541 and LY294002 (40 lM) in-
duced pronounced levels of apoptotic and total death in
NCS 48 h after treatment. As expected, zVAD-fmk, a pan-
caspase inhibitor (40 lM), suppressed apoptotic death and
increased NSC survival. In contrast, necrostatin cotreat-
ment did not affect cell death levels (Suppl. Figure 1a, b).
Interestingly, combined treatment by inhibitors had a dra-
matic effect on the induction of apoptosis in metastatic
WM9 cells, but only modest effects in the primary WM35
Fig. 3 Receptor expression and
spheroids formation in WM35
and WM9 melanoma cell lines.
a and b Surface and total
expression levels of NGFR,
TNFR1, FAS and CD133 in
WM35 and WM9 human
melanoma lines. % Antigen-
positive cells are indicated.
c Spheroid formation by WM35
cells in serum-free media
supplemented with FGF2
(20 ng/ml), EGF (20 ng/ml) and
insulin (5 lg/ml). Phase-
contrast images are shown.
d NSC (control) and WM9
melanoma cells after 6 days of
incubation in the similar serum-
free media with supplements.
e Surface expression of
indicated receptors on WM35
cells after cell culture growth in
two types of media. f Apoptotic
levels after treatment of WM35
cells that were grown on the
complete (WM35) or serum-
free media with supplements
(WM35-SF). Apoptosis was
induced by combination of
TRAL (50 ng/ml) ? CHX
(1 lg/ml) or TNFa (20 ng/ml)
? CHX. Levels of apoptosis
were determined using PI
staining and cell cycle-apoptotic
analysis. Error bars represent
mean ± SD (p\ 0.05,
Student’s t test). Stars indicate
significant difference
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cells (that were even less pronounced than effects in NSC)
(Suppl. Figure 1c–e). A substantial difference between
RGF WM35 and metastatic WM9 melanoma cells in the
response to IKK-NF-jB inhibition appears to reflect a
distinctive role for inflammatory gene expression [52]
during melanoma progression. Caspase inhibitor zVAD-
fmk (rather than Necrostatin-1) substantially down-
regulated levels of total and apoptotic death in WM9 cells
(Suppl. Figure 1c–e). SB203580, a MAPK p38 inhibitor,
did not change the proapoptotic effects of BMS345541 in
both WM35 and WM9 cells (Suppl. Figure 1d). Taken
together, the data obtained demonstrate a prevalence of
apoptotic versus necroptotic response in WM9 melanoma
cells after treatment with the indicated inhibitors. In con-
trast, WM35 cells exhibited pronounced resistance to
apoptotic and necrotic death in these conditions.
WM793 and FEMX melanoma cells with low
metastatic potential: regulation of cell death
and stemness
We additionally performed a comparison of WM793
(VGP; BRAF V600E) and FEMX (low metastatic; BRAF
wt) melanoma cells, which have previously demonstrated
functional and metabolic similarity [53]. Both WM793 and
FEMX cell lines exhibited high levels of SOX2 expression
with a preferential nuclear localization, and already men-
tioned a substantial difference in levels of Nestin expres-
sion and its location (Figs. 1c and 4a). We hypothesized
that the WM793 cell population consisted of two sub-
populations of the ‘‘early’’ (Nestin-negative) and ‘‘more
mature’’ (Nestin-positive) cells. High levels of phospho-
ERK are colocalized with Nestin-positive WM793 cells
(Fig. 4a). In contrast, all FEMX cells were Nestin-positive
with relatively low Nestin levels in the cell bodies and with
pronounced localization of Nestin in the cell neurites.
Furthermore, CD133 and COX2 protein expression was
almost undetectable in WM793 cells, while it was easily
detected in the FEMX cells (Fig. 4a). The difference in
total CD133 expression levels between two melanoma li-
nes was really striking. FACS analysis also revealed a
difference in surface receptor expression in WM793 versus
FEMX cells (Fig. 4b). Indeed, surface expression levels of
CD133 could be detected in 9 % FEMX and 2 % WM793
cells. Total levels of CD133 (after cell permeabilization)
were substantially higher in FEMX cells compared to
WM793: 19 % positive cells with 29 MFI and 3 % positive
cells with 15 MFI, respectively (Fig. 4b, c). On the other
hand, EGFR and NGFR surface expression was sig-
nificantly downregulated in FEMX, compared to WM793
cells (Fig. 4b). It should be mentioned that the FEMX cell
population represented a combination of multiple clones,
and prolonged selection allowed to isolate both low
metastatic and high metastatic subpopulations [54].
We addressed probable differences in the induction of
distinct cell death pathways in WM793 and FEMX me-
lanoma lines. First, we investigated regulation of cell sig-
naling pathways in WM793 and FEMX cells by small
molecule inhibitors, BMS345541 and LY294002 (40 lM),
4-8 h after treatment (Fig. 5a, b). Certain differences in
SOX2 protein levels, but relatively similar levels of
NANOG were observed in WM793 compared to FEMX
cells before and after the indicated treatment. Combined
treatment by BMS345541 and LY294002 increased protein
expression of SOX2 in both melanoma lines. Second, there
was an asymmetry in action of these inhibitors: LY204002
alone and, especially, in combination with BMS345541
decreased levels of phospho-AKT in WM793 cells, but not
in FEMX cells 4 h after treatment. On the other hand, both
BMS345541 and LY204002 alone or in combination effi-
ciently decreased the ratio of phospho-IKK/total IKK,
while the ratio of phospho-p65/total p65 NF-jB did not
reflected changes in IKK activity (Fig. 5a). On the other
hand, ERK1/2 activity increased upon suppression of AKT
and IKK in WM793 cells. Treatment with BMS345541
alone strongly increased p53 protein levels (Fig. 5a). Ac-
tivation of Capase-9 and Caspase-3 via specific cleaved
forms and Capase-3-dependent inactivation of PARP-1 by
its cleavage were modestly induced after treatment with
LY204002 alone and dramatically increased after com-
bined treatment with LY204002 and BMS345541 in
WM793, but not in FEMX cells (Fig. 5a). A similar picture
of PARP-1 cleavage was also observed 8 h after combined
treatment (Fig. 5b). In contrast, high protein expression of
cFLIP p55 and p32 was observed in FEMX, but not in
WM793 cells (Fig. 5a).
To determine the extent of the induction of apoptosis and
total cell death in WM793 and FEMX melanoma cells after
small molecule inhibitor treatment, we used several ap-
proaches: (i) cell cycle-apoptosis analysis of PI stained nuclei
48 h after treatment followed by flow cytometry (Fig. 5b;
Suppl. Figure 2b); and (ii) detection of levels of total death
using Trypan blue staining and light microscopy (Fig. 5d, e);
(iii) the pan-caspase inhibitor zVAD (40 lM) was used to
further confirm the involvement of caspase-dependent apop-
totic signaling pathways. Results of cell cycle-apoptosis ana-
lysis (48 h after treatment) clearly demonstrated the protective
effects of zVAD, but not Necrostatin-1 (both at dose 40 lM)
on apoptotic death induced by a combination of BMS345541
and LY294002 (Fig. 5b; Suppl. Figure 2b). Non-efficient
suppression of AKT activity by LY204002 alone or in com-
binationwithBMS345541 in FEMXcells correlatedwith their
resistance to proapoptotic treatment (Fig. 5b). Finally and
surprisingly, total levels of cell death induced by BMS345541
and LY294002 alone or in combination were significantly
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decreased in FEMX but not in WM793 cells by Necrostatin-1
(Fig. 5c). This indicates involvement of necroptosis in the
induction of death of FEMX cells. Levels of RIP1, a critical
signaling kinase for induced necroptosis, were substantially
higher in FEMX cells compared to WM793 cells based on
immunostaining and confocalmicroscopy (Fig. 4a, the bottom
panel) or Western analysis (Fig. 5a).
Since Western blotting also demonstrated an upregula-
tion of MAPK p38 levels by BMS345541 (Suppl. Fig-
ure 2a), we additionally used a combination of
BMS345541 and SB203580 (an inhibitor of p38) for
upregulation of apoptosis in melanoma cells. Combined
treatment with these inhibitors further increased apoptotic
levels in WM793, indicating a prosurvival role for both
IKKb and MAPK p38 (Suppl. Figure 2b). As expected, the
presence of zVAD decreased apoptotic levels induced by
these inhibitors. In general, combined treatment with
BMS345541 and LY294002 demonstrated strong death-
inducing effects via apoptosis and/or necroptosis in some
melanoma lines, such as WM9 and WM793 and several
others, but was not a universal inducer of high levels of cell
death for other melanoma cells, such as WM35 or FEMX,
probably due to a compensatory activation of alternative
pathways.
In contrast, TRAIL in combination with CHX effec-
tively induced TRAIL/DR5-mediated apoptosis and
upregulated total death levels in both WM793 and FEMX
cells, due to evident surface expression of DR5/TRAIL-R2
(Suppl. Figure 2c, d). Since both WM793 and FEMX cells
produce and secrete IL8 at high levels (Fig. 2e), we added
Fig. 4 Melanoma cell lines, WM793 and FEMX, express stem cell
and proapoptotic markers. a Confocal analysis of images after
immunostaining using rabbit polyclonal Ab to SOX2, a pluriopotency
marker (green) and monoclonal antibody to Nestin, an early
neuroprogenitor marker (red). Bar = 50 lm. An additional immunos-
taining with anti phospho-ERK (green) and anti-Nestin (red), anti-
STAT3 (green) and anti-COX2 (red), anti-SOX2 and anti-CD133,
anti-FAS (green), anti-RIP1 (green) Abs was also performed.
b Surface expression levels of NGFR, CD133, FAS, DR5 and
TNFR1 in NSC and WM793 and FEMX melanoma cells. Percentage
of positive cells is indicated. c CD133 total expression in WM793 and
FEMX cells was determined after permeabilization of the plasma
membranes with 0.5 % NP40 and immunostaining followed by FACS
analysis. Median fluorescence intensity (MFI) and % positive cells (in
red, after subtraction of nonspecific level) are shown
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anti-IL8 inhibitory antibody (5 lg/ml) before initiation of
TRAIL-mediated apoptosis. Apoptotic levels were notably
increased in these conditions (Suppl. Figure 2f). This
highlights an anti-apoptotic role for endogenous IL8 se-
cretion in melanoma cells. Interestingly, TRAIL?CHX
induced relatively similar levels of apoptosis in WM793
and FEMX cells, in spite of increased levels of cFLIP
(p55, p32 and p25) in FEMX cells (Fig. 5a). Since FEMX
cells possess substantially higher levels of RIP1 (Figs. 4a
and 5a), we decided to evaluate induction of necroptosis
in FEMX cells using the canonical TNFa?CHX
treatment.
We previously observed efficient induction of both
apoptosis and necroptosis by TNFa?CHX in NSC, which
possess high surface expression of TNFR1/2 (Fig. 2c).
However, TNFR surface expression was detected at low
levels in most melanoma lines. In contrast, total intracellular
levels of TNFR1 inWM793 and FEMX cells were relatively
high (Fig. 6a). Both melanoma lines expressed RIP1, with
the highest levels in FEMX (Figs. 4a and 5a). Cell cycle-
apoptosis analysis demonstrated substantial levels of
TNF?CHX induced cell death in WM793 and FEMX me-
lanoma cells, which, however, were not suppressed until the
basal levels of cell death in the presence of zVAD in FEMX
cells (Fig. 6b, c). On the other hand, Necrostain-1 (40 lM),
an inhibitor of RIP1 kinase activity and necroptosis, sub-
stantially downregulated levels of total death induced by
TNF?CHX combination in FEMX, but not in WM793 cells
(Fig. 6d). These data demonstrated a prominent TNF-in-
duced necroptosis in FEMX cells.
We further compared the capacity of WM793 and
FEMX cells to form spheroid cultures and to grow in
serum-free media supplemented with EGF, FGF2 and in-
sulin (Fig. 7). FEMX cells could effectively form spher-
oids, while WM793 started to die in these condition 4 days
after media transfer (Fig. 7c, d). Interestingly, surface ex-
pression of receptors (NGFR, DR5 and CD133) was de-
creased in serum-free media (Fig. 7a, b) and was correlated
with decreased levels of TRAIL-mediated death of FEMX
cells 24 h after treatment by TRAIL?CHX, while levels of
TNF-mediated apoptosis were not changed (Fig. 7e). An
additional ability for survival of FEMX cells in stress
conditions was probably correlated well with pronounced
endogenous COX2 expression, which is critical for
prostaglandin E2 (PGE2) production followed by the au-
tocrine and paracrine activation of PGE2-EP2/4 signaling
pathway [55]. NF-jB-dependent COX2 expression could
be further upregulated by exogenous TNFa (Fig. 7f).
Fig. 5 Effects of small
molecule inhibitors
BMS345541 and LY294002 on
cell signaling proteins and their
downstream targets in WM793
and FEMX melanoma cells.
a Western blot analysis of
indicated proteins was
performed 4 h after treatment of
cells with BMS345541 (20 lM)
and LY294002 (40 lM) alone
or in combination. b Cell cycle-
apoptosis analysis was
performed 48 h after
BMS345541 and LY294002
treatment using PI staining and
FACS analysis. c Total cell
levels were detected by Trypan
blue staining. Pooled results of
four independent experiments
with the indicated treatments are
shown for WM793 and FEMX
cells. zVAD (40 lM) and
Necrostatin (Nec, 40 lM) were
used. Error bars represent
mean ± SD (p\ 0.05,
Student’s t test). Stars indicate
significant difference
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COX2 upregulation could increase survival function in
many types of cancer cells including melanoma [56, 57].
Metastatic 1205Lu, A375, HHMSX and OM431
melanoma cells: biomarkers, stemness, resistance
to apoptosis and ability for trans-differentiation
As mentioned above, the 1205Lu melanoma line was
established using a lung metastasis originated from human
xenotransplant of WM793 melanoma cells in a nude mouse
[43]. Similarity and differences between the primary
WM793 cells and metastatic 1205Lu cells in signaling
pathways and apoptotic resistance were previously de-
scribed [53, 58]. One of the new differences discovered in
the current study was levels of Nestin protein expression in
these melanoma lines: there were two subpopulations
(negative and positive for Nestin) in WM793 and quite
homogenous distribution of Nestin in the 1205Lu cell
population (Figs. 1b and 2a, b). The basal phospho-ERK
demonstrated preferentially cytoplasmic location in both
lines (Figs. 2b and 8a). As we also demonstrated above, all
metastatic melanomas used in the present study, including
A375, were Nestin-positive with pronounced levels of
Nestin and SOX2 (Figs. 1c, d and 8a). 1205Lu cells ex-
pressed substantial levels of NGFR, TNFR1, FAS and DR5
on the cell surface, while the A375 cell line demonstrated
surface expressing of NGFR and TNFR1 only among
subpopulations of cells (Fig. 8b, c and e). Surface
Fig. 6 Total and apoptotic death induced by TNFa and cyclohex-
imide treatment of WM793 and FEMX melanoma cells. a Surface and
total TNFR1 expression in WM793 and FEMX melanoma cells.
Percentage positive cells is indicated; ns, non-specific staining. b and
c Cell cycle-apoptosis analysis of WM793 and FEMX melanoma cells
after treatment with cycloheximide (CHX) 1 lM, TNFa (20 ng/ml),
zVAD (40 lM) and Necrostatin (40 lM), alone or in combination.
48-60 h after treatment, cells were stained with PI and analyzed by
the flow cytometry. Percentage of cells at the cell cycle phases is
indicated in panels (b) and (c). d Total death levels were determined
by Trypan blue exclusion assay. Pooled results of four independent
experiments are shown for WM793 and FEMX melanoma cells. Error
bars represent mean ± SD (p\0.05, Student’s t test). Stars indicate
significant differences between the mock control cells, which were
treated in the absence of zVAD or Necrostatin (Sol, 0.1 % DMSO),
and cells that were treated with indicated reagents in the presence of
zVAD (40 lM) or Necrostatin (40 lM)
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expression of CD133 was quite noticeable in 1205Lu but not
seen in A375 cells. Surprisingly, A375 spheroid cultures
could grow in serum-free media with supplements, while
1205Lu cells did not produce spheroids in these conditions.
Instead, 1205Lu cells survived and could continue differ-
entiation as an adherent culture (see Suppl. Figure 4). In-
terestingly, the levels of surface expression of several
receptor proteins were not really decreased in A375 spheroid
culture (Fig. 8e). These receptor proteins were also main-
tained in 1205Lu cells at relatively equal levels in both the
completemedia and serum-freemedia (data not shown). This
correlated with the high levels of receptor-mediated cell
death (via DR5 or FAS) for both melanoma lines indepen-
dently of growth media; at the same time, TNF-induced
death was substantially higher in 1205Lu cells (Fig. 8g) due
to efficient surface expression of TNFR1 (Fig. 8b) and was
executed via the apoptotic pathway.
Two additional metastatic lines, OM431 ocular me-
lanoma and HHMSX melanoma also expressed SOX2 and
Nestin in concert with phospho-ERK and STAT3 (Suppl.
Figure 3A). One third of the OM431 cell population was
positive for surface NGFR, which was present, however, at
high levels inside the cells. The modest level of surface
expression was characteristic for FAS, while TNFR1, DR5
and CD133 were barely detectable on the cell surface, even
though they were present inside OM431 cells at high or
intermediate levels (Suppl. Figure 3B and C). On the other
hand, HHMSX cells had very low levels of surface
Fig. 7 Surface and total expression of receptors and TRAIL-induced
apoptosis in WM793 and FEMX melanoma cells that were grown as
adherent (media with 10 % FBS) or suspension (serum-free media
with supplements) cell cultures. a and b Surface expression of
receptors in WM793 and FEMX cells after culture in the complete
media or growth in serum-free media with supplements: EGF (20 ng/
ml, FGF2 (20 ng/ml) and insulin (5 lg/ml). Immunostaining recep-
tors and the flow cytometry were performed. c and d Spheroid culture
of FEMX cells and mixed (adherent and floating) culture of WM793
were observed after culturing in serum-free media with supplements.
e TRAIL?CHX and TRAIL?TNF-induced apoptosis was induced by
24 h-treatment of FEMX cells grown before treatment in the
complete media (for 2 days) or serum-free (SF) media with supple-
ments (for 3 days). PI staining of the cell nuclei and FACS analysis
were performed for the detection of apoptotic levels. f Effects of
TNFa (20 ng/ml) on expression levels of COX2 8 h after treatment of
FEMX cells. Confocal images are shown after immunostaining with
anti-STAT3 (green) and anti-COX2 (red) Abs. The bottom panel
demonstrates relative increase of COX2-positive cells after TNF
treatment
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expression of NGFR, TNFR1 and CD133, although these
proteins could be detected inside the cells (Suppl.
Figure 3B).
Both OM431 and HHMSX cells could grow in serum-
free media with supplements, and produced irregular
spheroids (Suppl. Figure 3A, the bottom panel); OM431
spheroids contained decreased levels of surface receptor
proteins (Suppl. Figure 3C). The native OM431 and
HHMSX cells only slightly responded to FasL- or TRAIL-
induced apoptotic signaling. However, TNF?CHX could
induce low to average levels of total cell death in HHMSX
and OM431 and this could be partially suppressed by either
zVAD or Necrostatin-1. This demonstrated a mixed type of
cell death signaling that resulted in both apoptosis and
necroptosis in OM431 cells (Suppl. Figure 3D). Taken
together, our data demonstrated that well pronounced
necroptosis was induced by a combination of TNF and
CHX in parallel with apoptosis in NSC as well as in FEMX
and OM431 melanoma cells. All three lines expressed high
levels of RIP1 (Fig. 5a and data not shown) and total
TNFR1, which was detected on the cell surface of NSC,
but mostly inside FEMX and OM431 cells.
Growth and differentiation of melanoma cell lines
in serum-free media with supplements
Suppl. Figure 4 demonstrates a summary picture of the
ability of melanoma cells to grow as spheroid cultures in
serum-free media supplemented with EGF (20 ng/ml),
FGF2 (20 ng/ml) and insulin (5 lg/ml). Interestingly,
Fig. 8 Metastatic melanoma lines, 1205Lu and A375, express stem
cell and proapoptotic markers. a Confocal analysis of 1205Lu and
A375 metastatic cells after immunostaining using rabbit polyclonal
Ab to SOX2, a pluriopotency marker (green) and monoclonal
antibody to Nestin, an early neuroprogenitor marker (red).
Bar = 50 lm. An additional immunostaining with anti-ERK-P and
anti-Nestin Abs was also performed. b and c Surface and total
expression levels of NGFR, TNFR1, CD133, FAS and DR5 in A375
and 1205Lu melanoma cells. Percentage of positive cells is indicated.
Total expression levels in 1205Lu and A375 cells were determined
after permeabilization of the plasma membranes with 0.5 % NP40
and immunostaining followed by FACS analysis. d and e A375
spheroids in serum-free media with supplements: EGF, FGF2 and
insulin. Surface expression of receptors in A375 spheroids is shown
on panel (e). f Comparison of apoptotic levels in A375 cell and
1205Lu cells after culturing in the complete or serum-free (SF) media
with supplements
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classic spheroid structure was characteristic of WM35
melanoma cells. Low-metastatic FEMX cells could also
grow as spheroids composed of relatively small numbers of
cells. WM793 and WM9 cells died several days after
transfer to serum-free media. OM431, A375 and HHMSX
cells produced irregular spheroid cultures also containing
cell suspension. Finally, 1205Lu adherent cells continued a
process of differentiation. HHMSX spheroid structures
were attached to dish’s matrix in serum-free media. Hence,
the ability to grow as a spheroid culture was a characteristic
feature for several melanoma lines used. Most of me-
lanoma lines did not notably increase the percentage of
CD133-positive cells after culturing as spheroids with but
one exception: HHMSX spheroids in serum-free media
supplemented with insulin (independently of the presence
of the exogenous EGF and FGF2) demonstrated an increase
in the levels of CD133-positive cells (Suppl. Figure 5d, e).
Increasing expression of CD133 in HHMSX cells is
reminiscent of the upregulation of CD133 expression in
spheroids of U97MG glioblastoma [51, 59].
Transfer to more restricted conditions, the serum-free
media supplemented only by insulin (5 lg/ml) without EGF
and FGF2, accelerated the trans-differentiation process for
1205Lu and OM431 cells along the neuronal pathway. In-
deed,well pronounced growth of neurites that contained both
Nestin, a neuroprogenitor marker, and doublecortin, a neu-
ronalmarker,was detected in 1235Lu andOM431metastatic
melanoma cells (Fig. 9). The presence of an additional
neuron-specific marker, beta-3-tubulin, was also observed
(Suppl. Figure 5a). These events occurred in concert with
nuclear translocation of phospho-ERK and STAT3 (Fig. 9,
Suppl. Figure 5a). Even at substantially low levels, com-
pared to young neurons, growth of neurites in 1205Lu and
OM431 cells was significant in the neuronal differentiation
media (Fig. 9e, f; Suppl. Figure 5a). A role of Rac1 in neu-
ronal growth by regulating the cytoskeleton of the growth
cone has been well established [60, 61]. Furthermore,
regulation of melanoma cell growth, cell shapes andmotility
by Rac1 was also observed [54]. We used previously
established culture of 1205Lu cells stably transfected with
dominant negative Rac1N17 [62] in differentiation ex-
periments. In the present study we observed substantial
suppression of neurite growth in these melanoma cells after
transfer to differentiation media (Fig. 9d, e).
In contrast to the neuronal pathway of trans-differen-
tiation for 1205Lu and OM431 cells, HHMSX melanoma
maintained compact adherent spheroid structures in dif-
ferentiation media without apparent neurite growth, but
with increasing expression of CD133, a cancer stem cell
marker (Suppl. Figure 5b–d). A375 cells also survived in
serum-free media with insulin, but exhibited a restricted
ability for trans-differentiation (Suppl. Figure 5f).
Discussion
During embryonic development, melanoblasts, the precur-
sors of melanocytes, emerge from a subpopulation of the
neural crest stem/progenitor cells (which give also rise to
the peripheral nervous system and several non-neural cell
types) and migrate along a dorsolateral pathway to colonize
skin. Melanoblasts populate the skin epidermis and further
differentiate into melanocytes. Continuous melanocyte
production in animal skin is dependent on the activity of
the self-renewing melanoblasts (also known as melanocyte
stem cells or regional neural crest stem cells) and of their
differentiation into melanocytes. Melanoblasts are prefer-
entially localized in the hair follicles of animal skin [63]. In
human skin, where hair follicles are relatively sparse,
melanoblasts also reside in the basal level of the interfol-
licular epidermis [64]. A rate of melanocyte proliferation
was substantially downregulated in the process of differ-
entiation: terminally differentiated melanocytes are long-
living cells with rare cell divisions (one every 143 days)
[20]. On the other hand, melanoblasts, maintain multipo-
tency: under specific conditions they can differentiate not
only into melanocytes but also into neurons and glial cells
[42]. Interestingly, a recent study demonstrates direct
conversion of human fibroblasts to functional melanocytes
by a combination of over-expressed transcription factors,
MITF, SOX10 and PAX3 [65].
Melanomas originate through somatic mutagenesis and
epigenetic regulation during melanoblast differentiation
into melanocytes and from young, actively proliferating
melanocytes [37, 66]. Transcription factor MITF plays a
central role in the terminal differentiation of melanocytes
through a positive control of the tyrosinase gene expression
and melanin production [67] and through a suppressive role
for genes controlling stemness, OCT4 and NANOG [68].
The characteristic features of melanoma lines used in the
current study, which were established from different phases
of tumor development, demonstrated both differences and
certain similarities. We observed average to high levels of
the expression of SOX2 and NANOG, master pluripotency
regulators, in all melanoma lines used in this study. A re-
cent publication highlighted the critical role of SOX2 in
regulation of self-renewal and tumorigenicity of human
melanoma-initiating cells [69]. On the other hand, Nestin,
an early neuroprogenitor marker, was almost completely
absent in radial growth phase WM35 melanoma cells and
in 60 % of a population of WM793 vertical growth phase
melanoma cells, but was detected in all metastatic me-
lanoma lines used in this study. SOX2 and Nestin coex-
pression was previously discovered in numerous samples
of metastatic melanomas [70]. Taken together, our data
highlighted well pronounced match of expression patterns
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of biomarkers in melanoma cells and in NSC. Comparable
expression levels of FAS and DR5 for NSC and some
melanoma lines underlined this similarity. In contrast, an
additional stem cell marker CD166/ALCAM was not de-
tectable in NSC, melanocytes, WM35 RGF and FEMX low
metastatic melanoma cells, but was strongly expressed in
A375 melanoma cells, emphasizing CD166 linkage with
melanoma progression [32].
On the other hand, surface expression of NGFR, a po-
tential marker of melanoma initiating cells [28], was found
at low levels (NSC; WM35 and FEMX), intermediate
levels (A375 and OM431) and high levels (WM793,
1235Lu and WM9). Interestingly, intracellular protein ex-
pression of NGFR was very high in WM35, A375, OM431
and HHMSX cells. CD133 surface expression was found at
high levels only in NSC, at intermediate to low levels in
FEMX and 1205Lu and at very low levels in WM35,
WM793, A375, OM431 and HHMSX cells. CD133 total
protein expression was also substantially higher than sur-
face expression in WM35, WM9, WM793, FEMX, A375,
OM431 and HHMSX cells, suggesting regulation of pro-
tein trafficking of receptors in these cells. Indeed, a role of
FAP-1 for negative regulation of FAS receptor surface
expression is well known [71, 72]. It is likely that a similar
Fig. 9 a Neuronal differentiation of NSC (10 days) in serum-free
differentiation media supplemented with B27 that contains insulin
(5 lg/ml). b and c Neuronal pathway of differentiation of 1205Lu and
OM431 melanoma cells (10 days) in the differentiation media with
the B27 supplement. Confocal images were developed after im-
munostaining using rabbit polyclonal Ab to SOX2, a pluriopotency
marker (green) and monoclonal antibody to Nestin, an early
neuroprogenitor marker; polyclonal Ab to doublecortin, a neuronal
marker (green) and monoclonal Ab to Nestin (red); polyclonal Ab to
phospho-ERK (green) and PI, polyclonal Ab to STAT3 (green) and PI
(red). Bar = 50 lm. Images from independent experiments: (I), (Ia)
and (Ib); (IIIa), (IIIb) and (IIIc). d 1205Lu cells, which were stably
transfected with dominant-negative Rac1N17, after 10 days in
differentiation media. e and f Relative length of Nestin-containing
neurites before (day 0) and 10 days after differentiation was
determined using 5 random areas of images. Error bars represent
mean ± SD (p\ 0.05, Student’s t test). Stars indicate significant
difference in relative neurite length for normal 1205Lu cells at days 0
and 10; double star indicates significant difference between control
and Rac1N17-transfected 1205Lu cells at day 10
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mechanism can regulate NGFR surface expression, due to a
similar NGFR/FAP-1 intracellular interaction [73].
Many investigations including our previous study
demonstrated enrichment of a spheroid culture of glioblas-
tomaU87MGby cancer stem cells after several passages [51,
59]. A similar approach was used for the isolation of a tu-
morigenic subpopulation with stem cell properties in me-
lanoma, which also exhibited the ability for mesenchymal
differentiation [47]. We observed relatively low CD133
expression on the cell surface of melanoma spheroids, which
was modestly increased only in the HHMSX spheroid cul-
ture. The absence of enrichment of CD133 and CD20
biomarker expression in melanoma spheroid cultures was
highlighted in a previously published paper [74]. Recently
OCT4 overexpression driven by lentiviral OCT4 was used
for infection of WM35 cells resulting in their dedifferen-
tiation, which was associated with cancer stem cell pheno-
types including significant increase of expression levels of
endogenous NANOG and KLF4, as well as stem cell
biomarkers, NGFR and ABCB5, but not CD133. Increased
tumorigenicity of WM35-OCT4 cells was also observed
[75]. In the current study we have not targeted identification
of new biomarkers for melanoma cells; instead we have
highlighted a differential ability of distinct melanoma lines
to grow as spheroid cultures.
The central question of this study is regarding the plas-
ticity of the neuronal pathway of trans-differentiation in
melanoma. We did not observed dedifferentiation of
metastatic melanoma cells via overexpression of the
pluripotency factors and the subsequent induction of a new
differentiation program. Instead, we observed a massive
trans-differentiation along the neuronal pathway in the
metastatic melanoma cells, 1235Lu and OM431, in the re-
stricted culture conditions. The clinical cases of malignant
melanomas with neural differentiation were previously ob-
served [76, 77]. In contrast, HHMSX cells demonstrated cell
survival, increased total protein expression of CD133, a
marker for cancer stem cells, and the absence of neural dif-
ferentiation after culturing in serum-free media supple-
mented with insulin. Furthermore, several melanoma lines,
includingWM793, died in these conditions, probably due to
non-balanced autophagy followed by necrosis. In this re-
spect, it was interesting to compare the resistant 1205Lu cells
and the sensitive WM793 cells. A recent publication has
demonstrated significant levels of the protective autophagy
in metastatic 1205Lu cells, compared to the parent primary
WM793 cells [78].
One of the aims of the present study was to further in-
vestigate the apoptotic and necroptotic death signaling
events among melanoma cell lines from different stage of
tumor progression. Similar to NSC, FEMX melanoma cells
with high RIP1 kinase levels and total TNFR1 levels re-
sponded by development of both necroptosis and apoptosis
after TNF?CHX treatment, while WM793 cells demon-
strated a proapoptotic commitment,whichwas also observed
among other melanoma lines, excluding HHMSX. Taken
together, our results reveal that necroptosis could be induced
at substantial levels in two melanoma lines, FEMX and
OM431, while, in general, the mitochondrial pathway of
apoptosis is prevalent in melanomas. Involvement of
necroptotic signaling in induction of cell death, at least in
some melanoma lines, may constitute a possibility for
regulation of death in these resistant to treatment cancer
cells.
In summary, all melanoma lines used in the current
study express well pronounced levels of pluripotency
markers, SOX2 and NANOG. There was a trend for in-
creasing expression of the early neuroprogenitor marker-
Nestin, during melanoma progression. Most of melanoma
lines, especially WM35, FEMX and A375, could grow as
spheroid cultures in serum-free media with supplements,
similar to NSC. Such growth, beside well-known increase
in tumorigenicity, was accompanied by significant down-
regulation of surface expression levels of FAS, DR5 and
NGFR1 and the corresponding decrease in death levels
after signaling via FAS and DR5. Finally, it was possible to
induce neural trans-differentiation of 1205Lu and OM431
cells confirmed by the expression of neuronal markers,
doublecortin and b3-Tubulin, and by intensive neurite
growth directed by RAC1. These data indicate a relative
plasticity of differentiated melanoma cells and the possi-
bility for their trans-differentiation without ectopic over-
expression of OCT4 and OCT4-induced dedifferentiation.
In conclusion, we observed four types of response of me-
lanoma cells to restricted culturing conditions (serum-free
serum ? insulin): (i) cancer cell death probably via de-
structive autophagy (WM793) [78], (ii) maintenance of
cancer cell stable differentiation (A375) or (iii) trans-dif-
ferentiation (1205Lu), and (iv) cancer cell survival with
increased proportions of the stem cell subpopulation
(HHMSX). As a result of such trans-differentiation me-
lanoma cells can acquire some characteristic features of
young neurons and neuroblastoma cells. We hypothesized
that the ability to differentiate for 1205Lu and OM431 cells
was correlated with the maintenance of sensitivity to the
induction of cell death; in contrast, the maintenance of the
spheroid phenotype by HHMSX cells was linked with their
resistance to cell death.
Materials and methods
Reagents
Fibronectin, laminin and polyornithine were obtained from
Sigma-Aldrich (St. Louis, MO, USA). PI3 K inhibitor
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LY294002, IKK inhibitor BMS345541, MAPK p38 in-
hibitor SB203580, and pan-caspase inhibitor zVAD-fmk
were purchased from Calbiochem (La Jolla, CA, USA).
Human soluble Killer-TRAIL (recombinant), Fas-Ligand
(recombinant), anti-human TRAIL and anti-human Fas-
Ligand antibodies were purchased from Alexis (San Diego,
CA, USA); human TNFa, IL6 and IL8 were obtained from
R&D Systems (Minneapolis, MN, USA).
Human embryonic neural stem cells (NSC)
Cryopreserved human embryonic neural stem cells (NSC)
were obtained from Gibco/Life Technologies (Carlsbad,
CA, USA) as a commercially available product (N7800-
200). The cells were derived from NIH approved H9
(WA09) human embryonic stem cells. The cells were
plated in 6-well culture plates coated with fibronectin and
incubated at 37 C in complete growth medium NSC/SFM,
which contained serum-free DMEM/F12 supplemented
with 2 mM GlutaMAX, bFGF (20 ng/ml), EGF (20 ng/ml)
and StemPRO neural supplement (2 %). All reagents were
obtained from Gibco/Life Technologies (Carlsbad, CA,
USA).
Neuronal differentiation of human neural stem cells
in culture
Neural stem cells were plated on polyornithine- and
laminin-coated 6-well plates, which contained similarly
coated cover slips, in complete NSC/SFM. After 2 days,
neuronal differentiation was initiated by neuronal differ-
entiation media, which contains Neurobasal medium, B-27
Serum-free supplement (2 %) and 2 mM GlutaMAX
(Gibco/Life Technologies). Medium was changed every
two days. A neuronal phenotype was confirmed using im-
munofluorescence detection 6-10 days after initiation of
differentiation.
U87MG glioblastoma cells
Human glioblastoma (U87MG or HTB-14, ATCC) cell line
was obtained from ATCC (Manassas, VA, USA). Cells
were cultured in DMEM supplemented with 10 % FBS and
1 % pyruvate. For neurosphere formation, U87MG
glioblastoma cells were cultured in the serum-free media
DMEM/F12 supplemented with 2 mM GlutaMAX, bFGF
(20 ng/ml), EGF (20 ng/ml) and B27 supplement (2 %).
All reagents were obtained from from Gibco/Life Tech-
nologies (Carlsbad, CA, USA). After 15-20 passages,
spheroid U87MG culture was significantly enriched by
CD133? cells. For immunocytochemical analysis U87MG
spheroids were attached to fibronectin matrix.
Human melanoma cells
Human melanoma cell lines 1205Lu, WM9, WM35,
WM793 [38], FEMX, HHMSX [39], OM431 and A375
were maintained in DMEM medium supplemented with
10 % fetal bovine serum, L-glutamine and antibiotics. Cells
were grown at 37 C with 5 % CO2. A375 cell line was
obtained from American Type Culture Collection (ATCC,
Manassas, VA, USA). For spheroid formation, melanoma
cells were plated in 6-well culture plates and incubated at
37 C in complete growth medium NSC/SFM, which
contained serum-free DMEM/F12 supplemented with
2 mM GlutaMAX, bFGF (20 ng/ml), EGF (20 ng/ml) and
StemPRO neural supplement (2 %) that also included in-
sulin (5 lg/ml). All reagents were obtained from from
Gibco/Life Technologies (Carlsbad, CA, USA). For in-
duction of neuronal pathway of differentiation, melanoma
cells were cultured in differentiation media as described
above for neuronal differentiation of neural stem cells.
Immunocytochemistry analysis
Cells were fixed with 4 % paraformaldehyde in PBS for
20 min. Immunochemical staining was performed using
standard protocols. Cells were stained for the undifferen-
tiated NSC marker, Nestin (using mAb from Millipore,
Temecula, CA, USA), and for the neuronal markers, dou-
blecortin and beta3-Tubulin, using Abs from Cell Signaling
(Danvers, MA, USA). Additional Abs against biomarkers
include: SOX2, GFAP, STAT3, phospho-ERK (Cell Sig-
naling), CD133 (Miltenyi Biotec, Auburn, CA) and COX2
(Cayman Chemical, Ann Arbor, MI). The secondary Abs
were Alexa Fluor 594 goat anti-mouse IgG and Alexa
Fluor 488 goat anti-rabbit IgG from Molecular Probes/Life
Technologies (Carlsbad, CA, USA). A laser scanning
confocal microscope (Nikon TE 2000 with EZ-C1 soft-
ware, Tokyo, Japan) was used for immunofluorescence
imaging.
FACS analysis of surface and total levels of cell
receptors
Surface levels of NGFR, TRAIL-R2/DR5, FAS, TNFR1,
TNFR2, CD133 and CD166 on human cell lines were de-
termined by staining with a PE-conjugated Abs to the
corresponding human proteins (R&D System, Minneapolis,
MN, USA; eBioscience, San Diego, CA, USA; and Mil-
tenyi Biotec, Auburn, CA, USA) and subsequently by use
of flow cytometry. For detection of total levels of antigen
proteins, cells were fixed and permeabilized using 0.5 %
NP40 in PBS. PE-conjugated nonspecific mouse IgG1 was
used as an immunoglobulin isotype control. A FACS
Calibur flow cytometer (Becton Dickinson, Mountain
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View, CA, USA) and the CellQuest program were used to
perform flow cytometric analysis. All experiments were
independently repeated 3-5 times.
Cell death studies
For induction of apoptosis, cells were exposed to small
molecule inhibitors of cell signaling pathways. Further-
more, apoptosis was induced by TRAIL, TNFa, FasL and
CHX alone or in combination. Apoptosis levels were then
assessed by propidium iodide (PI) staining and quantifying
the percentage of hypodiploid nuclei (pre-G1) using FACS
analysis or by quantifying the percentage of Annexin-V-
FITC-positive and PI-positive cells (BD Pharmingen, San
Diego, CA), performed on a FACS Calibur flow cytometer
(Becton Dickinson) using the CellQuest program. Trypan
blue exclusion test was used for determination of cell
viability and total death levels. Pan-caspase inhibitor,
zVAD-fmk (40 lM) and RIP1 kinase inhibitor, Necro-
statin-1 (40 lM), were added to cell cultures 1 h before
induction of death signaling.
Western blot analysis
Total cell lysates (50 lg protein) were resolved on SDS-
PAGE, and processed according to standard protocols. The
monoclonal antibodies used for Western blotting included:
anti-b-Actin (Sigma, St. Louis, MO, USA); anti-caspase-3
(Cell Signaling, Danvers, MA, USA). The polyclonal an-
tibodies used included anti-phospho-p44/p42 MAP kinase
(T202/Y204) and anti-p44/p42 MAP kinase; anti-phospho-
JNK and anti-JNK1-3; anti-phospho-AKT (S473) and anti-
AKT; anti-phospho-p65 (S536) NF-jB and anti-p65 NF-
jB, anti-phospho-STAT3 (Y705) and anti-STAT3; anti-
p53, anti-SOX2, anti-NANOG, anti-caspase-9, anti-RIP1
and anti-PARP-1 (Cell Signaling, Danvers, MA, USA);
anti-FAS, and anti-DR5/TRAIL-R2 (Alexis, San Diego,
CA, USA).The secondary antibodies were conjugated to
horseradish peroxidase; signals were detected using the
ECL system (Thermo Scientific, Rockford, IL, USA).
ELISA for IL6, IL8, and TNFa detection
in the media
The ELISA kits for detection of human cytokines were
purchased from R&D System, Minneapolis, MN, USA and
eBioscience, San Diego, CA, USA.
Statistical analysis
Data from four to five independent experiments were cal-
culated as means and standard deviations. Comparisons of
results between treated and control groups were made by
the Students’ t tests. A p value of 0.05 or less between
groups was considered significant.
Acknowledgments We would like to thank Drs. Peter Grabham and
Howard Lieberman for advice, critical reading of the manuscript and
discussion. This work was supported by Pilot Grant of the Department
of Dermatology, Columbia University (P30AR044531-11, Project
GG006336) and NIH Grant 5R01-ES12888-07.
Conflict of interest The authors declare that there are no conflicts
of interest.
Compliance with Ethical Standards Animals were not used in
this research. Participation of human subjects did not occur in this
study.
References
1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S,
Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N,
Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J,
Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S,
Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C,
Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-
Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flana-
gan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL,
Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ,
Wooster R, Stratton MR, Futreal PA (2002) Mutations of the
BRAF gene in human cancer. Nature 417:949–954
2. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins
CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G,
Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK,
Trent JM, Meltzer PS (2003) High frequency of BRAF mutations
in nevi. Nat Genet 33:19–20. doi:10.1038/ng1054
3. Tsao H, Goel V, Wu H, Yang G, Haluska FG (2004) Genetic
interaction between NRAS and BRAF mutations and PTEN/
MMAC1 inactivation in melanoma. J Invest Dermatol
122:337–341. doi:10.1046/j.0022-202X.2004.22243.x
4. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner
H, Cho KH, Aiba S, Brocker EB, LeBoit PE, Pinkel D, Bastian BC
(2005) Distinct sets of genetic alterations in melanoma. N Engl J
Med 353:2135–2147. doi:10.1056/NEJMoa050092
5. Tsao H, Zhang X, Fowlkes K, Haluska FG (2000) Relative re-
ciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous
melanoma cell lines. Cancer Res 60:1800–1804
6. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M,
Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D,
Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D,
Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K,
Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen
G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald
JE, Wagner SN, Hoon DS, Schadendorf D, Lander ES, Gabriel
SB, Getz G, Garraway LA, Chin L (2012) A landscape of driver
mutations in melanoma. Cell 150:251–263. doi:10.1016/j.cell.
2012.06.024
7. Vultur A, Villanueva J, Herlyn M (2011) Targeting BRAF in Ad-
vanced Melanoma: a First Step toward Manageable Disease. Clin
Cancer Res 17:1658–1663. doi:10.1158/1078-0432.ccr-10-0174
8. Lipson EJ, Drake CG (2011) Ipilimumab: an anti-CTLA-4 anti-
body for metastatic melanoma. Clin Cancer Res 17:6958–6962.
doi:10.1158/1078-0432.CCR-11-1595
1012 Apoptosis (2015) 20:996–1015
123
9. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA,
Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke
MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X,
Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ,
Wigginton JM, Gupta A, Sznol M (2013) Nivolumab plus ip-
ilimumab in advanced melanoma. N Engl J Med 369:122–133.
doi:10.1056/NEJMoa1302369
10. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P,
Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D,
Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day
SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop
K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur AG
(2011) Improved survival with vemurafenib in melanoma with
BRAF V600E mutation. N Engl J Med 364:2507–2516. doi:10.
1056/NEJMoa1103782
11. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA,
Sosman JA, O’Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman
PB (2010) Inhibition of mutated, activated BRAF in metastatic
melanoma. N Engl J Med 363:809–819. doi:10.1056/NEJMoa
1002011
12. Nowell PC (1976) The clonal evolution of tumor cell populations.
Science 194:23–28
13. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next
generation. Cell 144:646–674. doi:10.1016/j.cell.2011.02.013
14. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas
I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C,
Marais R (2010) Kinase-dead BRAF and oncogenic RAS coop-
erate to drive tumor progression through CRAF. Cell 140:209–
221. doi:10.1016/j.cell.2009.12.040
15. Vultur A, Villanueva J, Krepler C, Rajan G, Chen Q, Xiao M, Li
L, Gimotty PA, Wilson M, Hayden J, Keeney F, Nathanson KL,
Herlyn M (2014) MEK inhibition affects STAT3 signaling and
invasion in human melanoma cell lines. Oncogene 33:1850–
1861. doi:10.1038/onc.2013.131
16. Krasilnikov M, Ivanov VN, Dong J, Ronai Z (2003) ERK and
PI3 K negatively regulate STAT-transcriptional activities in hu-
man melanoma cells: implications towards sensitization to apop-
tosis. Oncogene 22:4092–4101
17. Watson IR, Li L, Cabeceiras PK, Mahdavi M, Gutschner T,
Genovese G, Wang G, Fang Z, Tepper JM, Stemke-Hale K, Tsai
KY, Davies MA, Mills GB, Chin L (2014) The RAC1 P29S
Hotspot Mutation in Melanoma Confers Resistance to Pharma-
cological Inhibition of RAF. Cancer Res 74:4845–4852. doi:10.
1158/0008-5472.CAN-14-1232-T
18. Martz CA, Ottina KA, Singleton KR, Singleton KR, Jasper JS,
Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang
T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL,
Rathmell JC, Flaherty KT, Wargo JA, McDonnell DP, Sabatini
DM, Wood KC (2014) Systematic identification of signaling
pathways with potential to confer anticancer drug resistance. Sci
Signal 7:ra121. doi:10.1126/scisignal.aaa1877
19. Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z,
Chakraborty A, Bacchiocchi A, Koo A, Haskins JW, Bosenberg
MW, Stern DF (2013) Genotype-selective combination therapies
for melanoma identified by high-throughput drug screening.
Cancer Discov 3:52–67. doi:10.1158/2159-8290.CD-12-0408
20. Tomasetti C, Vogelstein B (2015) Cancer etiology. Variation in
cancer risk among tissues can be explained by the number of stem
cell divisions. Science 347:78–81. doi:10.1126/science.1260825
21. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid
tumours: accumulating evidence and unresolved questions. Nat
Rev Cancer 8:755–768. doi:10.1038/nrc2499
22. Magee JA, Piskounova E, Morrison SJ (2012) Cancer stem cells:
impact, heterogeneity, and uncertainty. Cancer Cell 21:283–296.
doi:10.1016/j.ccr.2012.03.003
23. Kreso A, Dick JE (2014) Evolution of the cancer stem cell model.
Cell Stem Cell 14:275–291. doi:10.1016/j.stem.2014.02.006
24. Smalley KS, Herlyn M (2009) Integrating tumor-initiating cells
into the paradigm for melanoma targeted therapy. Int J Cancer
124:1245–1250. doi:10.1002/ijc.24129
25. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser
AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C,
Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH (2008)
Identification of cells initiating human melanomas. Nature
451:345–349. doi:10.1038/nature06489
26. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM,
Morrison SJ (2008) Efficient tumour formation by single human
melanoma cells. Nature 456:593–598. doi:10.1038/nature07567
27. Held MA, Curley DP, Dankort D, McMahon M, Muthusamy V,
Bosenberg MW (2010) Characterization of melanoma cells ca-
pable of propagating tumors from a single cell. Cancer Res
70:388–397. doi:10.1158/0008-5472.CAN-09-2153
28. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson
DL, Ly DP, Butler PD, Yang GP, Joshua B, Kaplan MJ, Lon-
gaker MT, Weissman IL (2010) Human melanoma-initiating cells
express neural crest nerve growth factor receptor CD271. Nature
466:133–137. doi:10.1038/nature09161
29. Lang D, Mascarenhas JB, Shea CR (2013) Melanocytes, me-
lanocyte stem cells, and melanoma stem cells. Clin Dermatol
31:166–178. doi:10.1016/j.clindermatol.2012.08.014
30. Murphy GF, Wilson BJ, Girouard SD, Frank NY, Frank MH
(2014) Stem cells and targeted approaches to melanoma cure.
Molecular Asp Med 39C:33–49. doi:10.1016/j.mam.2013.10.003
31. Redmer T, Welte Y, Behrens D, Fichtner I, Przybilla D, Wruck
W, Yaspo ML, Lehrach H, Schafer R, Regenbrecht CR (2014)
The nerve growth factor receptor CD271 is crucial to maintain
tumorigenicity and stem-like properties of melanoma cells. PLoS
ONE 9:e92596. doi:10.1371/journal.pone.0092596
32. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR
(2007) Increased expression of stem cell markers in malignant
melanoma. Mod Pathol 20:102–107. doi:10.1038/modpathol.
3800720
33. Ashkenazi A, Herbst RS (2008) To kill a tumor cell: the potential
of proapoptotic receptor agonists. J Clin Invest 118:1979–1990
34. Jin Z, El-Deiry WS (2005) Overview of cell death signaling
pathways. Cancer Biol Ther 4:139–163
35. Degterev A, Hitomi J, Germscheid M, Ch’en IL, Korkina O,
Teng X, Abbott D, Cuny GD, Yuan C, Wagner G, Hedrick SM,
Gerber SA, Lugovskoy A, Yuan J (2008) Identification of RIP1
kinase as a specific cellular target of necrostatins. Nat Chem Biol
4:313–321. doi:10.1038/nchembio.83
36. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G
(2010) Molecular mechanisms of necroptosis: an ordered cellular
explosion. Nat Rev Mol Cell Biol 11:700–714. doi:10.1038/
nrm2970
37. Vultur A, Herlyn M (2013) SnapShot: melanoma. Cancer Cell
23(706–706):e701. doi:10.1016/j.ccr.2013.05.001
38. Satyamoorthy K, DeJesus E, Linnenbach AJ, Kraj B, Kornreich
DL, Rendle S, Elder DE, Herlyn M (1997) Melanoma cell lines
from different stages of progression and their biological and
molecular analyses. Melanoma Res 7(Suppl 2):S35–42
39. Myklebust AT, Helseth A, Breistol K, Hall WA, Fodstad O
(1994) Nude rat models for human tumor metastasis to CNS.
Procedures for intracarotid delivery of cancer cells and drugs.
J Neurooncol 21:215–224
40. Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA,
Nathanson KL, Herlyn M, Smalley KS (2008) The mitogen-ac-
tivated protein/extracellular signal-regulated kinase kinase in-
hibitor AZD6244 (ARRY-142886) induces growth arrest in
melanoma cells and tumor regression when combined with
Apoptosis (2015) 20:996–1015 1013
123
docetaxel. Clin Cancer Res 14:230–239. doi:10.1158/1078-0432.
CCR-07-1440
41. Peter ME, Legembre P, Barnhart BC (2005) Does CD95 have
tumor promoting activities? Biochim Biophys Acta 1755:25–36
42. Kunisada T, Tezulka K, Aoki H, Motohashi T (2014) The
stemness of neural crest cells and their derivatives. Birth Defects
Res Part C 102:251–262. doi:10.1002/bdrc.21079
43. Juhasz I, Albelda SM, Elder DE, Murphy GF, Adachi K, Herlyn
D, Valyi-Nagy IT, Herlyn M (1993) Growth and invasion of
human melanomas in human skin grafted to immunodeficient
mice. Am J Pathol 143:528–537
44. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber
BL, Van Belle P, Elder DE, Herlyn M (2003) Constitutive mi-
togen-activated protein kinase activation in melanoma is medi-
ated by both BRAF mutations and autocrine growth factor
stimulation. Cancer Res 63:756–759
45. Tamada K, Chen L (2006) Renewed interest in cancer im-
munotherapy with the tumor necrosis factor superfamily mole-
cules. Cancer Immunol Immunother 55:355–362. doi:10.1007/
s00262-005-0081-y
46. Ivanov VN, Hei TK (2014) A role for TRAIL/TRAIL-R2 in ra-
diation-induced apoptosis and radiation-induced bystander re-
sponse of human neural stem cells. Apoptosis 19:399–413.
doi:10.1007/s10495-013-0925-4
47. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van
Belle PA, Xu X, Elder DE, Herlyn M (2005) A tumorigenic
subpopulation with stem cell properties in melanomas. Cancer
Res 65:9328–9337. doi:10.1158/0008-5472.CAN-05-1343
48. Karin M (2009) NF-kappaB as a critical link between inflam-
mation and cancer. Cold Spring Harb Perspect Biol 1:a000141.
doi:10.1101/cshperspect.a000141
49. Franke TF (2008) PI3 K/Akt: getting it right matters. Oncogene
27:6473–6488. doi:10.1038/onc.2008.313
50. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflam-
mation, and cancer. Cell 140:883–899. doi:10.1016/j.cell.2010.
01.025
51. Ivanov VN, Hei TK (2014) Radiation-induced glioblastoma sig-
naling cascade regulates viability, apoptosis and differentiation of
neural stem cells (NSC). Apoptosis 19:1736–1754. doi:10.1007/
s10495-014-1040-x
52. Grivennikov S, Karin M (2008) Autocrine IL-6 signaling: a key
event in tumorigenesis? Cancer Cell 13:7–9
53. Ivanov VN, Hei TK (2004) Arsenite sensitizes human melanomas
to apoptosis via tumor necrosis factor alpha-mediated pathway.
J Biol Chem 279:22747–22758
54. Bauer NN, Chen YW, Samant RS, Shevde LA, Fodstad O (2007)
Rac1 activity regulates proliferation of aggressive metastatic
melanoma. Exp Cell Res 313:3832–3839. doi:10.1016/j.yexcr.
2007.08.017
55. Chun KS, Surh YJ (2004) Signal transduction pathways
regulating cyclooxygenase-2 expression: potential molecular
targets for chemoprevention. Biochem Pharmacol 68:1089–1100
56. Ivanov VN, Partridge MA, Huang SX, Hei TK (2011) Suppres-
sion of the proinflammatory response of metastatic melanoma
cells increases TRAIL-induced apoptosis. J Cell Biochem
112:463–475. doi:10.1002/jcb.22934
57. Denkert C, Kobel M, Berger S, Siegert A, Leclere A, Trefzer U,
Hauptmann S (2001) Expression of cyclooxygenase 2 in human
malignant melanoma. Cancer Res 61:303–308
58. Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M,
Herlyn M, Smalley KS, Mahale A, Eroshkin A, Aaronson S,
Ronai Z (2007) Rewired ERK-JNK signaling pathways in me-
lanoma. Cancer Cell 11:447–460. doi:10.1016/j.ccr.2007.03.009
59. Hardee ME, Marciscano AE, Medina-Ramirez CM, Zagzag D,
Narayana A, Lonning SM, Barcellos-Hoff MH (2012) Resistance
of glioblastoma-initiating cells to radiation mediated by the tumor
microenvironment can be abolished by inhibiting transforming
growth factor-beta. Cancer Res 72:4119–4129. doi:10.1158/
0008-5472.CAN-12-0546
60. Grabham PW, Reznik B, Goldberg DJ (2003) Microtubule and
Rac 1-dependent F-actin in growth cones. J Cell Sci 116:
3739–3748. doi:10.1242/jcs.00686
61. Vadodaria KC, Brakebusch C, Suter U, Jessberger S (2013)
Stage-specific functions of the small Rho GTPases Cdc42 and
Rac1 for adult hippocampal neurogenesis. J Neurosci 33:1179–
1189. doi:10.1523/JNEUROSCI.2103-12.2013
62. Ivanov VN, Krasilnikov M, Ronai Z (2002) Regulation of Fas
expression by STAT3 and c-Jun is mediated by phosphatidyli-
nositol 3-kinase-AKT signaling. J Biol Chem 277:4932–4944
63. Nishimura EK (2011) Melanocyte stem cells: a melanocyte reservoir
in hair follicles for hair and skin pigmentation. Pigment Cell Me-
lanoma Res 24:401–410. doi:10.1111/j.1755-148X.2011.00855.x
64. Liu J, Fukunaga-Kalabis M, Li L, Herlyn M (2014) Develop-
mental pathways activated in melanocytes and melanoma. Arch
Biochem Biophys. doi:10.1016/j.abb.2014.07.023
65. Yang R, Zheng Y, Li L, Liu S, Burrows M, Wei Z, Nace A,
Herlyn M, Cui R, Guo W, Cotsarelis G, Xu X (2014) Direct
conversion of mouse and human fibroblasts to functional me-
lanocytes by defined factors. Nat Commun 5:5807. doi:10.1038/
ncomms6807
66. Uong A, Zon LI (2010) Melanocytes in development and cancer.
J Cell Physiol 222:38–41. doi:10.1002/jcp.21935
67. Chin L, Garraway LA, Fisher DE (2006) Malignant melanoma:
genetics and therapeutics in the genomic era. Genes Dev 20:
2149–2182
68. Cheli Y, Giuliano S, Botton T, Rocchi S, Hofman V, Hofman P,
Bahadoran P, Bertolotto C, Ballotti R (2011) Mitf is the key
molecular switch between mouse or human melanoma initiating
cells and their differentiated progeny. Oncogene 30:2307–2318.
doi:10.1038/onc.2010.598
69. Santini R, Pietrobono S, Pandolfi S, Montagnani V, D’Amico M,
Penachioni JY, Vinci MC, Borgognoni L, Stecca B (2014) SOX2
regulates self-renewal and tumorigenicity of human melanoma-
initiating cells. Oncogene 33:4697–4708. doi:10.1038/onc.2014.
71
70. Laga AC, Zhan Q, Weishaupt C, Ma J, Frank MH, Murphy GF
(2011) SOX2 and nestin expression in human melanoma: an
immunohistochemical and experimental study. Exp Dermatol
20:339–345. doi:10.1111/j.1600-0625.2011.01247.x
71. Ivanov VN, Lopez Bergami P, Maulit G, Sato TA, Sassoon D,
Ronai Z (2003) FAP-1 association with Fas (Apo-1) inhibits Fas
expression on the cell surface. Mol Cell Biol 23:3623–3635
72. Ivanov VN, Ronai Z, Hei TK (2006) Opposite roles of FAP-1 and
dynamin in the regulation of Fas (CD95) translocation to the cell
surface and susceptibility to Fas ligand-mediated apoptosis.
J Biol Chem 281:1840–1852
73. Irie S, Hachiya T, Rabizadeh S, Maruyama W, Mukai J, Li Y,
Reed JC, Bredesen DE, Sato TA (1999) Functional interaction of
Fas-associated phosphatase-1 (FAP-1) with p75(NTR) and their
effect on NF-kappaB activation. FEBS Lett 460:191–198
74. Ramgolam K, Lauriol J, Lalou C, Lauden L, Michel L, de la
Grange P, Khatib AM, Aoudjit F, Charron D, Alcaide-Loridan C,
Al-Daccak R (2011) Melanoma spheroids grown under neural
crest cell conditions are highly plastic migratory/invasive tumor
cells endowed with immunomodulator function. PLoS ONE
6:e18784. doi:10.1371/journal.pone.0018784
75. Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ, Gimotty PA,
Guerra M, Guo W, Xu X (2012) Acquired cancer stem cell
phenotypes through Oct4-mediated dedifferentiation. Oncogene
31:4898–4911. doi:10.1038/onc.2011.656
76. Reed RJ, Leonard DD (1979) Neurotropic melanoma. A variant
of desmoplastic melanoma. Am J Surg Pathol 3:301–311
1014 Apoptosis (2015) 20:996–1015
123
77. Su A, Dry SM, Binder SW, Said J, Shintaku P, Sarantopoulos GP
(2014) Malignant melanoma with neural differentiation: an excep-
tional case report and brief review of the pertinent literature. Am J
Dermatopathol 36:e5–9. doi:10.1097/DAD.0b013e31828cf90a
78. Kraya AA, Piao S, Xu X, Zhang G, Herlyn M, Gimotty P, Levine
B, Amaravadi RK, Speicher DW (2014) Identification of secreted
proteins that reflect autophagy dynamics within tumor cells.
Autophagy. doi:10.4161/15548627.2014.984273
Apoptosis (2015) 20:996–1015 1015
123
